Posted by Michael Wonder on 23 Nov 2022
InnoCare announces approval of Hibruka (orelabrutinib) for the treatment of mantle cell lymphoma in Singapore
22 November 2022 - InnoCare Pharma announced today that Hibruka (orelabrutinib) has been approved by the Health Sciences Authority of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
On 25 December 2020, orelabrutinib received approval from the China NMPA in two indications: the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma and the treatment of patients with relapsed or refractory mantle cell lymphoma.
At the end of 2021, orelabrutinib was included into National Reimbursement Drug List in China.
